Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

In the eight years since the FDA first ap­proved an on­colyt­ic virus as a can­cer ther­a­py, de­vel­op­ers have been striv­ing — and large­ly fail­ing — to bring …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.